MRUS - Merus reaches four-month high on upcoming AACR presentations

2023-03-15 12:01:09 ET

• Merus N.V. ( NASDAQ: MRUS ) added ~7% on Wednesday to reach the highest level since November after announcing that abstracts on its MCLA-158 and MCLA-129 product candidates were selected for presentations at the upcoming AACR Annual Meeting.
• The American Association for Cancer Research (AACR) Annual Meeting 2023 is scheduled to take place in Orlando, Florida, from Apr. 14 to Apr. 19.
• On Apr. 17, two presentations will focus on interim data for MCLA-158 (petosemtamab) in previously treated head and neck squamous cell carcinoma (HNSCC) and mid-stage data for the same candidate in advanced gastric/ esophageal adenocarcinoma.
• A day later, bispecific antibody MCLA-129 will be the subject of a poster presentation about its pre clinical mechanism of action. MCLA-129 is currently under development for certain solid tumors such as HNSCC and non-small cell lung cancer.
• Read: Seeking Alpha contributor Zach Bristow issued a Hold rating on Merus ( MRUS ) in December after the FDA required additional patient enrollment to support a marketing application for the company's bispecific antibody zenocutuzumab.

For further details see: